Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 16Gastrointestinal 10Tumor-Agnostic 6Thoracic 6Other solid neoplasm 6Gynecologic 4Genitourinary 2Plasma cell 1Other hematologic neoplasm 1Head & Neck 1CNS 1Breast 1

Conditions

Thyroid Neoplasms 1Ovarian Neoplasms 1Melanoma 1Glioblastoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × cobimetinib × CNS × Clear all
NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

ABM Therapeutics Corporation

Phase 1 Terminated
53 enrolled
CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡